NewLimit raises $130 million in Series B funding to combat aging using AI and genomics, led by Kleiner Perkins and supported by notable investors.

May 07, 2025•4 months ago

Amount Raised

$130 Million

Round Type

series b

South San FranciscoBiotechnology

Investors

Khosla VenturesDaniel GrossNat FriedmanPatrick CollisonGarry TanElad GilDimension CapitalFounders FundKleiner Perkins

Description

NewLimit, a biotech startup co-founded by Coinbase CEO Brian Armstrong, has secured $130 million in a Series B round. This funding aims to enhance their development of therapies to slow aging through AI-driven cell reprogramming. The total funding for NewLimit now exceeds $170 million. Notable investors include Kleiner Perkins, Founders Fund, and Khosla Ventures.

Company Information

Company

NewLimit

Location

South San Francisco, California, United States

About

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends